APUS Stock Overview
Operates as a clinical stage biopharmaceutical company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Apimeds Pharmaceuticals US, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.81 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$1.72 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| APUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | -2.6% | 3.9% |
| 1Y | n/a | -12.1% | 11.6% |
Return vs Industry: Insufficient data to determine how APUS performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how APUS performed against the US Market.
Price Volatility
| APUS volatility | |
|---|---|
| APUS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: APUS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine APUS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 2 | Erik Emerson | www.apimedsus.com |
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey.
Apimeds Pharmaceuticals US, Inc. Fundamentals Summary
| APUS fundamental statistics | |
|---|---|
| Market cap | US$25.46m |
| Earnings (TTM) | -US$1.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.1x
P/E RatioIs APUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APUS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.39m |
| Earnings | -US$1.39m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -49.6% |
How did APUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 06:03 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apimeds Pharmaceuticals US, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.